Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PI3K Pathway Activated Tumors”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Large-scale testing (Phase 3)Study completedNCT01572727
What this trial is testing

The Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 416
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)WithdrawnNCT01288092
What this trial is testing

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01833169
What this trial is testing

BKM120 for Patients With PI3K-activated Tumors

Who this might be right for
PI3K Pathway Activated Tumors
Novartis Pharmaceuticals 146
Not applicableEnrolling By InvitationNCT06943313
What this trial is testing

Breast Cancer PET/CT Imaging With 68Ga-pAKTi

Who this might be right for
Breast CancersPIK3CA Mutation-Related TumorsPI3K Pathway Activated Tumors+1 more
Fudan University 20
Testing effectiveness (Phase 2)Ended earlyNCT02023905
What this trial is testing

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Who this might be right for
Low Grade GliomaWorld Health Organization (WHO) Grade II AstrocytomasOligodendrogliomas+1 more
University of California, San Francisco 27
Testing effectiveness (Phase 2)Study completedNCT01297491
What this trial is testing

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 63
Large-scale testing (Phase 3)Not Yet RecruitingNCT04736589
What this trial is testing

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Who this might be right for
Breast Cancer
Peking Union Medical College 270
Testing effectiveness (Phase 2)Study completedNCT01339052
What this trial is testing

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Who this might be right for
Glioblastoma
Patrick Y. Wen, MD 65
Early research (Phase 1)Study completedNCT01470209
What this trial is testing

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Who this might be right for
Solid TumorsLung Cancer
Emory University 43
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70